澳大利亚PBS药品上市后再审查制度介绍及对我国的启示

李大双; 颜建周; 邵蓉

doi:10.6039/j.issn.1001-0408.2023.15.01

您当前的位置：

首页 >

文章列表页 >

澳大利亚PBS药品上市后再审查制度介绍及对我国的启示

药事管理 | 更新时间：2025-09-26

- 澳大利亚PBS药品上市后再审查制度介绍及对我国的启示
- Introduction of Australian post-market reviews of pharmaceutical benefits scheme subsidized medicines and its implication to China
- 中国药房 2023年34卷第15期页码：1793-1797
- 作者机构：
  
  中国药科大学国家药物政策与医药产业经济研究中心，南京　211198
- 作者简介：
  
  硕士研究生。研究方向：医药政策与法规。E-mail：lds0024@153.com
  教授，博士生导师，博士。研究方向：医药政策与法规。电话：025-86185188。E-mail：shaorong118@163.com
- 基金信息：
  
  国家自然科学基金项目(72274217)
- DOI：10.6039/j.issn.1001-0408.2023.15.01
  中图分类号： R95
- 收稿日期：2023-01-04，
  
  修回日期：2023-06-14，
  
  录用日期：2023-06-14，
  
  纸质出版日期：2023-08-15
- 稿件说明：
移动端阅览
李大双,颜建周,邵蓉.澳大利亚PBS药品上市后再审查制度介绍及对我国的启示[J].中国药房,2023,34(15):1793-1797.

LI Dashuang,YAN Jianzhou,SHAO Rong.Introduction of Australian post-market reviews of pharmaceutical benefits scheme subsidized medicines and its implication to China[J].ZHONGGUO YAOFANG,2023,34(15):1793-1797.
李大双,颜建周,邵蓉.澳大利亚PBS药品上市后再审查制度介绍及对我国的启示[J].中国药房,2023,34(15):1793-1797. DOI： 10.6039/j.issn.1001-0408.2023.15.01.

LI Dashuang,YAN Jianzhou,SHAO Rong.Introduction of Australian post-market reviews of pharmaceutical benefits scheme subsidized medicines and its implication to China[J].ZHONGGUO YAOFANG,2023,34(15):1793-1797. DOI： 10.6039/j.issn.1001-0408.2023.15.01.

摘要

目的

为加强我国医保目录内药品的准入后管理提供参考。

方法

介绍澳大利亚药品福利计划（PBS）上市后再审查（PMR）制度的基本情况、开展流程和实施成效，同时对我国医保目录类药品的准入后管理提出建议。

结果与结论

PMR制度体现了澳大利亚对PBS目录内药品进行全生命周期管理的理念，作为管理PBS药品的准入和调整的一种机制，可实现对PBS目录内药品的持续评估。其流程主要包括PBS药品审查启动前流程和PBS药品审查流程2种，涉及药品遴选、审查范围确定、实施管理等步骤。通过PMR，澳大利亚共完成了PBS目录内糖尿病、儿童哮喘、阿尔茨海默病等9个治疗领域的多个药品的审查。笔者建议我国可在制度层面完善药品准入后审查（明确审查对象的遴选标准和方法、主要程序和责任主体、保证审查过程公开透明）；明确国家医疗保障局或委托第三方机构，直至成立专门的技术机构负责这一工作；与此同时，进一步完善数据收集和监测系统的建设。

Abstract

OBJECTIVE

To provide a reference for strengthening the post-admission management of drugs on the medicare formulary in China.

METHODS

The basic situation， implementation process and effect of post-market reviews （PMR） were introduced after marketing approval of the Australian pharmaceutical benefits scheme （PBS） subsidized medicines. The suggestions were put forward for post-admission management of medicare formulary drugs in China.

RESULTS & CONCLUSIONS

PMR system exemplified Australia’s concept of life-cycle management of medicines on the PBS catalogue； as a mechanism for managing the admission and adjustment of PBS medicines， it provided a continuous evaluation of medicines in the PBS catalogue； the process mainly included two types： the pre-initiation process of PBS drug review and the PBS drug review process， involving steps such as drug selection， determination of review scope， and implementation management. Through PMR， Australia had completed the review of multiple medicines in nine treatment areas including diabetes， childhood asthma and Alzheimer’s disease in the PBS catalogue. The author suggests that China can improve the post-admission review of medicines at the institutional level （clarifying the selection criteria and methods of the review object， main procedures and responsible parties， and ensuring the transparency of the review process）； specify the National Healthcare Security Administration or the third-party organization until a special technical organization is established to take charge of this work； at the same time， further improve the construction of data collection and monitoring systems.

关键词

Keywords

references

应晓华 . 医保目录准入谈判与创新 [J ] . 中国社会保障， 2022 （ 9 ）： 43 .

应晓华 . 医保目录谈判续约规则逻辑 [J ] . 中国社会保障， 2022 （ 8 ）： 45 .

PBS . Post-market reviews of pharmaceutical benefits scheme subsidised medicines [EB/OL ] . （ 2022-12-09 ）[ 2022- 12-21 ] . https：//www.pbs.gov.au/info/reviews/subsidised-medicines-reviews https://www.pbs.gov.au/info/reviews/subsidised-medicines-reviews .

PBS . PBS post-market review framework-revised October，2022 [EB/OL ] . （ 2022-10-01 ）[ 2022-12-25 ] . https：//consultations.health.gov.au/technology-assessment-access-division/revised-pbs-post-market-review-framework/supporting_documents/Revised%20PBS%20PMR%20Framework%20%20Consultation%20draft.pdf https://consultations.health.gov.au/technology-assessment-access-division/revised-pbs-post-market-review-framework/supporting_documents/Revised%20PBS%20PMR%20Framework%20%20Consultation%20draft.pdf .

董心月，张伶俐，颜建周，等 . 基于药品再评价的医保目录动态调整风险控制机制研究：以澳大利亚为例 [J ] . 中国卫生事业管理， 2019 ， 36 （ 8 ）： 603 - 608 .

PBS . Pharmaceutical benefits scheme post-market reviews [EB/OL ] . （ 2014-10-01 ）[ 2022-12-25 ] . https：//www.pbs.gov.au/reviews/subsidised-medicines-reviews-files/post-market-review-framework-10-2014.pdf https://www.pbs.gov.au/reviews/subsidised-medicines-reviews-files/post-market-review-framework-10-2014.pdf .

PBS . Post-market review of pulmonary arterial hypertension （PAH） medicines [EB/OL ] . （ 2020-05-25 ）[ 2022-12-30 ] . https：//www.pbs.gov.au/info/reviews/post-market-review-pah https://www.pbs.gov.au/info/reviews/post-market-review-pah .

PBS . Completed post-market reviews [EB/OL ] . （ 2022-12-22 ）[ 2022-12-31 ] . https：//www.pbs.gov.au/info/browse/reviews https://www.pbs.gov.au/info/browse/reviews .

吴久鸿，王翔，赵绯丽 . 澳大利亚医保目录动态调整机制管理经验及启示 [J ] . 中国卫生经济， 2018 ， 37 （ 9 ）： 94 - 96 .

汤静琪，张晓 . 澳大利亚高值药物管理准入政策及对我国的启示 [J ] . 中国新药杂志， 2021 ， 30 （ 12 ）： 1073 - 1078 .

浏览量

420

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据